HCW Biologics Inc. received written notice on February 26, 2026, from the Nasdaq Capital Market Listing Qualifications Staff that it has regained compliance with all continued listing rules. This compliance follows an extension granted by the Nasdaq Hearings Panel on October 13, 2025, which required the Company to meet the Equity Rule (5550(b)(1)) by December 31, 2025, and all other listing rules by February 16, 2026. The Company remains subject to a Mandatory Panel Monitor for one year from February 26, 2026, meaning any future non-compliance with the Equity Rule will lead to immediate delisting proceedings without further cure periods. HCW Biologics is a clinical-stage biopharmaceutical company focused on developing immunotherapies to address chronic inflammation and age-related diseases. Its lead product candidate, HCW9302, an IL-2 fusion molecule, is currently in a Phase 1 clinical study for alopecia areata, initiated in November 2025. The Company also has two preclinical lead candidates, HCW11-018b (Big BiTE) for solid tumors and HCW11-040 (pembrolizumab-based immune checkpoint inhibitor), developed using its proprietary TRBC platform. A key part of the Company's strategy involves business development, having already entered into two licensing agreements for its proprietary molecules.